Business Wire

Red Hat Introduces Confirmed Sovereign Support for European Union

6.11.2025 09:00:00 CET | Business Wire | Press Release

Share

Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations.

More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain transparency, jurisdictional security, compliance and autonomy.

Red Hat Confirmed Sovereign Support is designed to address this growing demand from European leaders for operational sovereignty. It also builds on Red Hat’s decade-plus expertise in delivering support models for specific regions and industries, especially for customers operating in highly regulated markets or facing strict compliance requirements. Red Hat Confirmed Sovereign Support helps enhance systems security and protect operations of EU organizations, building on the trust that more than 20,000 organizations globally already place on Red Hat’s open hybrid cloud portfolio and technical support.

The sovereign mandate: The Red Hat advantage

Red Hat Confirmed Sovereign Support will offer the highest levels of technical expertise with localized technical support staff and greater independence from non-EU dynamics, which enhances operational resilience and supports business continuity goals. The offering extends Red Hat's commitment to empowering customers with the control, choice and transparency of open source technologies, delivered through key features, including:

  • Dedicated EU-Citizen staffing: Access to support expertise delivered by verified European Union citizens operating solely within the 27 EU member states.
  • Localized operational control: Reinforces that EU technical support oversees the provision of support services.
  • 24/7 in-region availability: Provides round-the-clock technical support delivered within the EU region, aligning with sovereignty and service continuity requirements.
  • Expansive local ecosystem: Red Hat's approach is further amplified by its robust ecosystem of more than 500 EU cloud partners, many of whom already offer sovereign clouds. This powerful network helps strategically reduce reliance on non-EU hyperscalers, providing customers with robust, local alternatives that align directly with regional regulatory policies and economic priorities.
  • Foundation for sovereign cloud: Red Hat Confirmed Sovereign Support is built to underpin Red Hat’s broader open hybrid cloud and AI portfolios, enabling organizations to deploy, run and maintain both current and future IT estates independently across any sovereign cloud environment.

Red Hat believes that the only credible path to digital sovereignty is a foundation built on open source, which inherently delivers the transparency and auditability that regulatory bodies and organizations require. This approach, centered on choice and control, fundamentally distinguishes Red Hat from proprietary "sovereign" offerings built on closed software and opaque architectures.

Availability

Red Hat Confirmed Sovereign Support will be available in early 2026. Interested parties should inquire with their local account executive for more details as they become available.

Supporting Quotes

Chris Wright, CTO and senior vice president, Global Engineering, Red Hat

“Digital sovereignty means keeping control over your own technology destiny, from data location to software and operations. Navigating the EU's stringent regulatory and compliance frameworks demands an open source-driven, transparent, auditable foundation and a local operational support model. Red Hat Confirmed Sovereign Support offers exactly that: a fully EU-anchored support experience, run by EU citizens for EU organizations backed by the trust of our open hybrid cloud portfolio.”

Hans Roth, senior vice president & general manager EMEA, Red Hat:

“Red Hat is making a clear, demonstrable investment in European digital sovereignty. European organizations require control over their infrastructure, and that control must start with the people who support it. With Red Hat Confirmed Sovereign Support, we are directly addressing this demand by delivering an EU-citizen-driven support team and workflow for our enterprise open source solutions. This offering underscores Red Hat’s commitment to empowering EU organizations to own their digital destiny and build upon our open hybrid cloud foundation for greater digital autonomy and resilience.”

Additional Resources

Connect with Red Hat

About Red Hat, Inc.

Red Hat is the open hybrid cloud technology leader, delivering a trusted, consistent and comprehensive foundation for transformative IT innovation and AI applications. Its portfolio of cloud, developer, AI, Linux, automation and application platform technologies enables any application, anywhere—from the datacenter to the edge. As the world's leading provider of enterprise open source software solutions, Red Hat invests in open ecosystems and communities to solve tomorrow's IT challenges. Collaborating with partners and customers, Red Hat helps them build, connect, automate, secure and manage their IT environments, supported by consulting services and award-winning training and certification offerings.

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company’s current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except as required by law, the company assumes no obligation to update or revise any forward-looking statements.

Red Hat and the Red Hat logo are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106455112/en/

Contacts

Media Contact:
John Terrill
jterrill@redhat.com
+1-571-421-8132

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye